Alimera Sciences Inc's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Alimera Sciences Inc's ROA in the second quarter of 2024?
Alimera Sciences Inc recorded a cumulative net loss of $-15 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -9.65%.

However, within the Healthcare sector 287 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2024 quarter, so far to 3392, from total ROA ranking in the first quarter of 2024 at 3606.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Total Assets Change	-3.33 %	215.75 %	259.71 %	255.04 %	225.61 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-15	-21	-20	-20	-24
Return On Assets (TTM)	-9.65 %	-13.95 %	-15.79 %	-20.16 %	-33.3 %
ALIM's Total Ranking	# 3392	# 3606	# 4209	# 3864	# 4254
Total Assets (TTM) in million	149	152	153	154	154
Seq. Total Assets Change	-1.99 %	-0.6 %	-0.61 %	-0.15 %	220.12 %
Seq. Net Income Change	-	-	-	-	-

ALIM's 5 Years Annual ROA >> Back to ALIM Management Effectiveness >> Compare ALIM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 100
Sector	# 288
Overall	# 3338

Return On Assets Statistics
High	Average	Low
123.47 %	-29.5 %	-171.17 %
(Jun 30 2019)		(Mar 31 2014)

Financial Statements
Alimera Sciences Inc's Assets	$ 149 million	ALIM's Balance sheet
Alimera Sciences Inc's Income	$ -3 million	Quarterly ALIM's Income Statement
ALIM's Income by Division		See ALIM's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	259.71 %	-27.2 %	8.27 %	7.43 %	-7.02 %
Total Assets in million	153	43	59	54	50
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-20	-18	-4	-5	-10
Annual Return On Assets	-13.14 %	-42.5 %	-7.47 %	-9.88 %	-20.76 %

ALIM's 5 Years Annual ROA >> Back to ALIM Management Effectiveness >> Compare ALIM ROA to its Competitors

More Return On Assets Ratios
ALIM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ALIM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ALIM's Competitors
Subscribers only: Roa for Alimera Sciences Inc's Suppliers
Subscribers only: Return On Assets for ALIM's Customers

You may also want to know
ALIM's Roi	ALIM's Inventory Turnover Ratio	ALIM's Growth Rates	ALIM's Dividend Comparisons
	ALIM's Profitability Ratios	ALIM's Asset Turnover Ratio	ALIM's Dividend Growth
ALIM's Roe	ALIM's Valuation Ratios	ALIM's Financial Strength Ratios	ALIM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.